Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Hudbay Minerals Inc. Ordinary Shares (Canada)Trade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Hudbay Minerals Inc. Ordinary Shares (Canada) vs Recursion Pharmaceuticals Inc — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $26.29 (market cap $11.24B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is far larger — about 5.3× Recursion Pharmaceuticals Inc's market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

HBMRXRX
Market Cap
$11.24B$2.14B
Volume
4,316,37430,789,535
Sector
Basic MaterialsHealth
52-Week High
$31.87$6.79
52-Week Low
$14.58$2.84
Typical Hold Time
0 Days22 Days
Enterprise Value
$11.30B$1.66B
Dividend Yield
0.11%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hudbay Minerals Inc. Ordinary Shares (Canada)

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.

The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HBM
100% Buy0% Sell
Avg holding period · 0 Days
RXRX
8% Buy92% Sell
Avg holding period · 22 Days

Top news

Latest headlines on both assets

About Hudbay Minerals Inc. Ordinary Shares (Canada)

Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.

Read more on HBM →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →